The objective of this study was to determine the factors associated with the occurrence of arterial vascular events in a multiethnic systemic lupus erythematosus (SLE) cohort. The PROFILE cohort, comprised SLE patients (n = 1333) of defined ethnicity from five different US institutions, was studied to determine demographic, clinical and biological variables associated with vascular events. An arterial vascular event (first episode) was either a myocardial infarction, angina pectoris and/or a vascular procedure for myocardial infarction, stroke, claudication and/or evidence of gangrene. Patient characteristics were analyzed by univariable and multivariable Cox proportional hazards regression analyses. One-hundred twenty-three (9.8%) patients had at least one incident arterial event. Age at cohort enrollment (HR = 1.04, 95% CI 1.03–1.06), smoking (HR = 2.20, 95% CI 1.40–3.46) and the CRP2* C alleles (HR = 1.91, 95% CI 1.04–3.49) were associated with a shorter time-to-the occurrence of arterial vascular events. Some clinical manifestations of disease activity were associated with a shorter time-to-occurrence [psychosis (HR = 2.21, 95% CI 1.10–4.44), seizures (HR = 1.85, 95% CI 1.00–3.24) and anaemia (HR = 1.83, 95% CI 1.02–3.31)], but others were not [arthritis (HR = 0.32, 95% CI 0.18–0.58)]. In conclusion, older patients, especially in the context of a predisposing environmental factor (smoking) and severe clinical manifestations, are at higher risk of having arterial vascular events. The genetic contribution of the variation at the CRP locus was not obscured by demographic or clinical variables. Awareness of these factors should lead to more effective management strategies of patients at risk for arterial vascular events.
1 Erkan D . Lupus and thrombosis . J Rheumatol2006; 33: 1715 – 1717 .
2.
2 Bessant R Hingorani A Patel L MacGregor A Isenberg DA Rahman A . Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus . Rheumatology (Oxford)2004; 43: 924 – 929 .
3.
3 Esdaile JM Abrahamowicz M Grodzicky T . Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus . Arthritis Rheum2001; 44: 2331 – 2337 .
4.
4 Manzi S Meilahn EN Rairie JE . Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study . Am J Epidemiol1997; 145: 408 – 415 .
5.
5 Abu-Shakra M Urowitz MB Gladman DD Gough J . Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death . J Rheumatol1995; 22: 1259 – 1264 .
6.
6 Bernatsky S Boivin JF Joseph L . Mortality in systemic lupus erythematosus . Arthritis Rheum2006; 54: 2550 – 2557 .
7.
7 Cervera R Khamashta MA Font J . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients . Medicine (Baltimore)2003; 82: 299 – 308 .
8.
8 Bjornadal L Yin L Granath F Klareskog L Ekbom A . Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95 . J Rheumatol2004; 31: 713 – 719 .
9.
9 Ward MM . Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus . Arthritis Rheum1999; 42: 338 – 346 .
10.
10 Mok CC Tang SS To CH Petri M . Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups . Arthritis Rheum2005; 52: 2774 – 2782 .
11.
11 Sarabi ZS Chang E Bobba R . Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus . Arthritis Rheum2005; 53: 609 – 612 .
12.
12 Chang ER Pineau CA Bernatsky S Neville C Clarke AE Fortin PR . Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus . J Rheumatol2006; 33: 1780 – 1784 .
13.
13 Martinez F Forner MJ Ruano M Abdilla N Oltra R Garcia-Fuster MJ . [Factors related to the risk of thrombosis in patients with lupus and antiphospholipid antibodies]. Med Clin (Barc)2006; 127: 405 – 408 .
14.
14 Font J Cervera R Ramos-Casals M . Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center . Semin Arthritis Rheum2004; 33: 217 – 230 .
15.
15 Martinez-Berriotxoa A Ruiz-Irastorza G Egurbide MV Rueda M Aguirre C . Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus . Lupus2004; 13: 927 – 933 .
16.
16 Horbach DA . van, OE, Donders, RC, Derksen, RH, De Groot, PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies . Thromb Haemost1996; 76: 916 – 924 .
17.
17 Bizzaro N Ghirardello A Zampieri S . Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study . J Thromb Haemost2007; 5: 1158 – 1164 .
18.
18 Bertolaccini ML Mepani K Sanna G Hughes GR Khamashta MA . Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus . Ann Rheum Dis2007; 66: 533 – 536 .
19.
19 Danowski A Kickler TS Petri M . Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus . J Rheumatol2006; 33: 1775 – 1779 .
20.
20 Booth S Chohan S Curran JC Karrison T Schmitz A Utset TO . Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus . Arthritis Rheum2007; 57: 845 – 850 .
21.
21 Fijnheer R Roest M Haas FJ De Groot PG Derksen RH . Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study . J Rheumatol1998; 25: 1737 – 1742 .
22.
22 Petri M . The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort . Thromb Res2004; 114: 593 – 595 .
23.
23 Petri M Roubenoff R Dallal GE Nadeau MR Selhub J Rosenberg IH . Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus . Lancet1996; 348(9035): 1120 – 1124 .
24.
24 Toloza SM Uribe AG McGwin G . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events . Arthritis Rheum2004; 50: 3947 – 3957 .
25.
25 Alarcón GS McGwin G Petri M Reveille JD Ramsey-Goldman R Kimberly RP . Baseline characteristics of a multiethnic lupus cohort: PROFILE . Lupus2002; 11: 95 – 101 .
26.
26 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271 – 1277 .
27.
27 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1997; 40: 1725 .
28.
28 Gladman DD Goldsmith CH Urowitz MB . The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison . J Rheumatol2000; 27: 373 – 376 .
29.
29 Alarcón GS McGwin G Petri M . Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort . PLoS Med2006; 3: e396 .
30.
30 Szalai AJ Wu J Lange EM . Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level . J Mol Med2005; 83: 440 – 447 .
31.
31 Szalai AJ Alarcón GS Calvo-Alén J . Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events . Rheumatology (Oxford)2005; 44: 864 – 868 .
32.
32 Petri M Spence D Bone LR Hochberg MC . Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices . Medicine (Baltimore)1992; 71: 291 – 302 .
33.
33 Ockene IS Miller NH . Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction . Circulation1997; 96: 3243 – 3247 .
34.
35.
35 Costenbader KH Kim DJ Peerzada J . Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis . Arthritis Rheum2004; 50: 849 – 857 .
36.
36 Ward MM Studenski S . Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking . Arch Intern Med1992; 152: 2082 – 2088 .
37.
37 Ghaussy NO Sibbitt W Bankhurst AD Qualls CR . Cigarette smoking and disease activity in systemic lupus erythematosus . J Rheumatol2003; 30: 1215 – 1221 .
38.
38 Bessant R Duncan R Ambler G . Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study . Arthritis Rheum2006; 55: 892 – 899 .
39.
39 Ahmad Y Shelmerdine J Bodill H . Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype . Rheumatology (Oxford)2007; 46: 983 – 988 .
40.
40 Calvo-Alén J Toloza SM Fernandez M . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients . Arthritis Rheum2005; 52: 2060 – 2068 .
41.
41 Jewell ML McCauliffe DP . Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment . J Am Acad Dermatol2000; 42: 983 – 987 .
42.
42 Rahman P Gladman DD Urowitz MB . Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus . J Rheumatol1998; 25: 1716 – 1719 .
43.
43 Yanbaeva DG Dentener MA Creutzberg EC Wesseling G Wouters EF . Systemic effects of smoking . Chest2007; 131: 1557 – 1566 .
44.
44 Bermudez EA Rifai N Buring JE Manson JE Ridker PM . Relation between markers of systemic vascular inflammation and smoking in women . Am J Cardiol2002; 89: 1117 – 1119 .
45.
45 Almeida OP Xiao J . Mortality associated with incident mental health disorders after stroke . Aust N Z J Psychiatry2007; 41: 274 – 281 .
46.
46 Cocito L Favale E Reni L . Epileptic seizures in cerebral arterial occlusive disease . Stroke1982; 13: 189 – 195 .
47.
47 Sanna G D'Cruz D Cuadrado MJ . Cerebral manifestations in the antiphospholipid (Hughes) syndrome . Rheum Dis Clin North Am2006; 32: 465 – 490 .
48.
48 Bertoli AM Vilá LM Apte M . Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual . Rheumatology (Oxford)2007; 46: 1471 – 1476 .
49.
49 Russell AI Cunninghame Graham DS Shepherd C . Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus . Hum Mol Genet2004; 13: 137 – 147 .
50.
50 Zee RY Ridker PM . Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis . Atherosclerosis2002; 162: 217 – 219 .
51.
51 Lange LA Carlson CS Hindorff LA . Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events . JAMA2006; 296: 2703 – 2711 .
52.
52 Morita A Nakayama T Doba N Hinohara S Soma M . Polymorphism of the C-reactive protein (CRP) gene is related to serum CRP level and arterial pulse wave velocity in healthy elderly Japanese . Hypertens Res2006; 29: 323 – 331 .
53.
53 Crawford DC Sanders CL Qin X . Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey . Circulation2006; 114: 2458 – 2465 .
54.
54 Mok MY Chan EY Fong DY Leung KF Wong WS Lau CS . Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus . J Rheumatol2005; 32: 622 – 628 .
55.
55 Tarr T Lakos G Bhattoa HP Shoenfeld Y Szegedi G Kiss E . Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients . Lupus2007; 16: 39 – 45 .
56.
56 Henderson SO Haiman CA Wilkens LR Kolonel LN Wan P Pike MC . Established risk factors account for most of the racial differences in cardiovascular disease mortality . PLoS ONE2007; 2: e377 .
57.
57 Kronmal RA McClelland RL Detrano R . Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA) . Circulation2007; 115: 2722 – 2730 .
58.
58 Muñoz-Rodríguez FJ Reverter JC Font J . Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome . Haematologica2000; 85: 632 – 637 .
59.
59 Brouwer JL Bijl M Veeger NJ Kluin-Nelemans HC . van der Meer, J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus . Blood2004; 104: 143 – 148 .
